Severine Roy

Villejuif, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy.

Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy.

Journal: EMBO molecular medicine

Published: October 09, 2025

International real-world study of combination immunotherapy sequences in metastatic melanoma.

International real-world study of combination immunotherapy sequences in metastatic melanoma.

Journal: Journal for immunotherapy of cancer

Published: October 08, 2025

Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.

Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.

Journal: Nature

Published: August 17, 2025

Hexokinase 2 is an RNA-binding protein that regulates mRNA translation independently of glycolysis and induces melanoma cell proliferation.

Hexokinase 2 is an RNA-binding protein that regulates mRNA translation independently of glycolysis and induces melanoma cell proliferation.

Journal: PLoS biology

Published: January 08, 2025

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 22, 2023

Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma.

Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma.

Journal: Current oncology reports

Published: May 03, 2023

Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy.

Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: September 28, 2022

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.

Journal: Journal for immunotherapy of cancer

Published: May 31, 2022

Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma.

Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma.

Journal: Cancers

Published: May 09, 2022

A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma.

A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 12, 2021

Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy.

Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy.

Journal: Cancer cell

Published: April 09, 2021

Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy.

Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy.

Journal: JCO precision oncology

Published: February 25, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026